Your protection starts here.

Pathology group

Type of pathology and reference situation (histological subtype of reference to diagnosis and initial stage):

Conditions for application (if clinical, to be decided in multidisciplinary group consultation):

Central nervous system

Pilocytic astrocytoma, grade I

Age at diagnosis: ≥ 21 years and ≤ 60 years

5 years from the date of the first antineoplastic therapeutic intervention

Grade I cerebral meningiomas

Complete surgical resection

2 years from the end of the last therapeutic protocol and without recurrence

And

Without radiotherapy

And

Without radiotherapy

And

Without cognitive or neurological deficit

Non‑progressive cerebral meningiomas

Stability on brain imaging for 5 years in all cases

5 years from the end of the last therapeutic protocol and without recurrence

And

Absence of cognitive or neurological deficit

Thyroid

Papillary or follicular carcinoma, stage I

Age at diagnosis: < 45 years

2 years from the end of the last therapeutic protocol and without recurrence

Papillary carcinoma, stage I or II

Age at diagnosis: ≥ 45 years

5 years from the end of the last therapeutic protocol and without recurrence

Breast

Lobular or ductal carcinoma in situ (without microinvasion)

Treatment carried out in accordance with the European consensus (ESMO Guidelines and St. Gallen International Consensus)

2 years from the end of the last therapeutic protocol and without recurrence

Ductal carcinoma in situ, with one or more areas of microinvasion (rupture of the basement membrane) not exceeding 1 mm (in greatest dimension) and which, on axillary assessment (sentinel node or axillary clearance), show no metastases in the removed lymph node(s)

Treatment carried out in accordance with the European consensus (ESMO Guidelines and St. Gallen International Consensus)

5 years from the end of the last therapeutic protocol and without recurrence

Skin

Melanoma in situ without microinvasion or Clark level I (confined to the epidermis)

Complete excision

2 years from the end of the last therapeutic protocol and without recurrence

And

Absence of dysplastic nevus syndrome

Uterus

Cervical intraepithelial neoplasia or carcinoma in situ without microinvasion

Treatment carried out in accordance with the national protocol in force or the applicable European guidelines at the time of diagnosis

2 years from the end of the last therapeutic protocol and without recurrence

Testicle

Pure seminomas, stage I

-

2 years from the end of the last therapeutic protocol and without recurrence

Pure seminomas, stage II

-

5 years from the end of the last therapeutic protocol and without recurrence

Non‑seminomatous or mixed tumours, stages I or II

-

5 years from the end of the last therapeutic protocol and without recurrence

Pathology group

Type of pathology and reference situation (reference histological subtype at diagnosis and initial stage)

Conditions for application (if clinical, to be decided in multidisciplinary group consultation)

Time limit

Prostate

Prostate adenocarcinoma, stage T1N0M0 or

T2aN0M0, PSA < 10 ng/ml and Gleason score ≤ 6

PSA after radical prostatectomy (measurement carried out less than 6 months ago): < 0.1 ng/ml

2 years from the end of the last therapeutic protocol and without recurrence

OR

PSA after conformational radiotherapy or brachytherapy (measurement carried out less than 6 months ago): < 1.5 ng/ml

Prostate adenocarcinoma not treated under active surveillance, stage ≤ T1c, PSA ≤ 10 ng/ml and Gleason score ≤ 6

Age at diagnosis: > 55 years

2 years from the end of the last therapeutic protocol and without recurrence

And

Histology: adenocarcinoma strictly intraglandular;

number of positive biopsies ≤ 2 and ≤ 50% of malignant tissue per fragment

Not having undergone any treatment (namely hormone therapy)

Kidney

Clear cell carcinoma, stage T1N0M0 grade 1 of Fuhrman

Age at diagnosis: > 50 years

5 years from the end of the last therapeutic protocol and without recurrence

Chromophobe cell carcinoma, stage T1N0M0

-

5 years from the end of the last therapeutic protocol and without recurrence

Colon and rectum

Adenocarcinoma, stage 0 (pTis)

Age at diagnosis: > 50 years

2 years from the end of the last therapeutic protocol and without recurrence

Adenocarcinoma, stage I (pT1N0M0)

Age at diagnosis: > 50 years

5 years from the end of the last therapeutic protocol and without recurrence

Haematopoietic system

Acute promyelocytic leukaemia (APL), subtype M3 of acute myeloid leukaemia (AML3), regardless of the number of leukocytes at the time of diagnosis

Without major complications during treatment

5 years from the end of the last therapeutic protocol and without recurrence

Chronic myeloid leukaemia (CML)

Active treatment

5 years from diagnosis

And

Quantification of the BCR‑ABL transcript strictly undetectable with detection techniques in force at the time the insurance policy is taken out, and for a continuous period of 36 months prior to it, with the techniques considered valid at that time

Burkitt leukaemia or lymphoma / acute lymphoblastic leukaemia L3 (LAL‑L3)

Age at diagnosis: ≤ 60 years

5 years from diagnosis

And

Complete treatment

And

General condition according to the ECOG (Eastern Cooperative Oncology Group) scale: 0 and 1

Hodgkin’s lymphomas

Stage 1A after a post‑treatment follow‑up period

2 years from the end of the last therapeutic protocol and without recurrence

Stage 1B and 2A after a post‑treatment follow‑up period

5 years from the end of the last therapeutic protocol and without recurrence